BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rustichelli C, Lo Castro F, Baraldi C, Ferrari A. Targeting pituitary adenylate cyclase-activating polypeptide (PACAP) with monoclonal antibodies in migraine prevention: a brief review. Expert Opinion on Investigational Drugs 2020;29:1269-75. [DOI: 10.1080/13543784.2020.1811966] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 González-hernández A, Condés-lara M, García-boll E, Villalón CM. An outlook on the trigeminovascular mechanisms of action and side effects concerns of some potential neuropeptidergic antimigraine therapies. Expert Opinion on Drug Metabolism & Toxicology 2021;17:179-99. [DOI: 10.1080/17425255.2021.1856366] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
2 Moody TW, Jensen RT. Pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide [Part 1]: biology, pharmacology, and new insights into their cellular basis of action/signaling which are providing new therapeutic targets. Curr Opin Endocrinol Diabetes Obes 2021;28:198-205. [PMID: 33449573 DOI: 10.1097/MED.0000000000000617] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Moody TW, Jensen RT. Pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide (Part 2): biology and clinical importance in central nervous system and inflammatory disorders. Curr Opin Endocrinol Diabetes Obes 2021;28:206-13. [PMID: 33481421 DOI: 10.1097/MED.0000000000000621] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Togha M, Ghorbani Z, Ramazi S, Zavvari F, Karimzadeh F. Evaluation of Serum Levels of Transient Receptor Potential Cation Channel Subfamily V Member 1, Vasoactive Intestinal Polypeptide, and Pituitary Adenylate Cyclase-Activating Polypeptide in Chronic and Episodic Migraine: The Possible Role in Migraine Transformation. Front Neurol 2021;12:770980. [PMID: 35002925 DOI: 10.3389/fneur.2021.770980] [Reference Citation Analysis]
5 Marynissen H, Buntinx L, Bamps D, Depre M, Ampe E, Van Hecken A, Gabriel K, Sands S, Vargas G, de Hoon J. First-in-human development of a pharmacodynamic biomarker for PAC1 receptor antagonists using intradermal injections of maxadilan. Clin Transl Sci 2022. [PMID: 35621246 DOI: 10.1111/cts.13309] [Reference Citation Analysis]
6 González-Hernández A, Marichal-Cancino BA, Villalón CM. The impact of CGRPergic monoclonal antibodies on prophylactic antimigraine therapy and potential adverse events. Expert Opin Drug Metab Toxicol 2021;17:1223-35. [PMID: 34535065 DOI: 10.1080/17425255.2021.1982892] [Reference Citation Analysis]
7 Tasma Z, Siow A, Harris PWR, Brimble MA, Hay DL, Walker CS. Characterisation of agonist signalling profiles and agonist-dependent antagonism at PACAP-responsive receptors: Implications for drug discovery. Br J Pharmacol 2021. [PMID: 34612509 DOI: 10.1111/bph.15700] [Reference Citation Analysis]
8 Ferreira KS, Dhillon H, Velly AM. The role of a potential biomarker in patients with migraine: review and new insights. Expert Rev Neurother 2021;21:817-31. [PMID: 34210227 DOI: 10.1080/14737175.2021.1951236] [Reference Citation Analysis]
9 Sokolov AY, Osipchuk AV, Skiba IB, Amelin AV. The Role of Pituitary Adenylate Cyclase-Activating Polypeptide and Vasoactive Intestinal Peptide in Migraine Pathogenesis. Neurochem J 2022;16:31-8. [DOI: 10.1134/s1819712422010123] [Reference Citation Analysis]
10 Bainomugisa CK, Sutherland HG, Parker R, Mcrae AF, Haupt LM, Griffiths LR, Heath A, Nelson EC, Wright MJ, Hickie IB, Martin NG, Nyholt DR, Mehta D. Using Monozygotic Twins to Dissect Common Genes in Posttraumatic Stress Disorder and Migraine. Front Neurosci 2021;15:678350. [PMID: 34239411 DOI: 10.3389/fnins.2021.678350] [Reference Citation Analysis]